USSTOCK.TODAY
Regular Market
Log in Sign up

Croda emerges as beauty company on Volufiline's Ozempic-face treatment effect

The Telegraph ·

PFE Pfizer Inc
$28.40 +0.42%
View chart & analysis →
  1. 1Croda's Volufiline sales surged 270% in the first half of the year.
  2. 2Croda's stock price rose 25% from its August 2025 low.
  3. 3Estee Lauder has begun selling a 92% concentrated version of a Croda ingredient.

So what's the key point?

Sales of products containing Croda ingredients have increased significantly. As Estee Lauder began using this ingredient, Croda's stock price also rose 25%.

Source The Telegraph · View original ↗

Related 3-line summaries

Analysts Raise Price Targets for Pfizer TIKR · 2d agoRevolution Medicine Shares Fall 6% and Zealand Pharma Announces Clinical Results BioPharma Dive · 3d agoPfizer prepares for loss of drug exclusivity and raises 2026 revenue guidance Trefis +2 · 4d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news